ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sovleplenib acetate

Also written as “HMPL-523 Acetate Tablets (Test Formulation)” and “HMPL-523 Acetate Tablets (Reference Formulation)”.

Its studies are led by HUTCHMED.

Furthest: phase 1, since Sep 11, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HUTCHMED10 open or runningphase 1since Sep 11, 2025Sep 11, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2025First study: phase 1 study in HealthyFirst studyNCT07331194 · 54 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07331194Healthy · China1CompletedNov 28, 202554

How it is read

Names in the registry

  • “HMPL-523 Acetate Tablets (Test Formulation)”, 1 entry
  • “HMPL-523 Acetate Tablets (Reference Formulation)”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.